Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

254 ARTÍCULOS , VIENDO DEL 166 AL 180

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects

Villain N, Planche V, Levy R.

Rev Neurol (Paris). 2022 Dec;178(10):1011-1030. doi: 10.1016/j.neurol.2022.06.012. Epub 2022 Sep 29.

Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers

Duong MT, Wolk DA.

Curr Neurol Neurosci Rep. 2022 Nov;22(11):689-698. doi: 10.1007/s11910-022-01232-4. Epub 2022 Oct 3.

Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors

Hajjar I, Yang Z, Okafor M, Liu C, Waligorska T, Goldstein FC, Shaw LM.

JAMA Netw Open. 2022 Oct 3;5(10):e2235068. doi: 10.1001/jamanetworkopen.2022.35068.

[Biomarkers for the diagnosis of cognitive impairment - Recommendations from the Swiss Memory Clinics]

Popp J, Georgescu D, Bürge M, Mundwiler-Pachlatko E, Bernasconi L, Felbecker A.

Praxis (Bern 1994). 2022;111(13):738-744. doi: 10.1024/1661-8157/a003913.

Objectifying Subjective Cognitive Decline: The Prognostic Role of Alzheimer Biomarkers

Zetterberg H, Schott JM.

Neurology. 2022 Oct 24;99(17):735-736. doi: 10.1212/WNL.0000000000201172.

Cerebrovascular damage in subjective cognitive decline: A systematic review and meta-analysis

Pitti H, Diaz-Galvan P, Barroso J, Badji A, Olofsson JK, Westman E, Ferreira D, Cedres N.

Ageing Res Rev. 2022 Dec;82:101757. doi: 10.1016/j.arr.2022.101757. Epub 2022 Oct 12.

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA.

JAMA Neurol. 2022 Dec 1;79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392.

The omega-3 index in Alzheimer's disease: Ready for prime time?

Yassine HN.

Am J Clin Nutr. 2022 Dec 19;116(6):1474-1475. doi: 10.1093/ajcn/nqac248.

Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Roveta F, Cermelli A, Boschi S, Ferrandes F, Grassini A, Marcinnò A, Spina M, Rubino E, Borsello T, Vercelli A, Rainero I.

J Alzheimers Dis. 2022;90(4):1381-1393. doi: 10.3233/JAD-220515.

Editorial: Blood-Based Biomarkers for Alzheimer's Disease: Are We There Yet?

Tariot P.

J Prev Alzheimers Dis. 2022;9(4):565-566. doi: 10.14283/jpad.2022.88.

Diverse and Composite Roles of miRNA in Non-Neuronal Cells and Neuronal Synapses in Alzheimer's Disease

Li X, Chen SC, Ip JPK.

Biomolecules. 2022 Oct 17;12(10):1505. doi: 10.3390/biom12101505.

Is Mitochondria DNA Variation a Biomarker for AD?

Gao R, Ma SL.

Genes (Basel). 2022 Oct 3;13(10):1789. doi: 10.3390/genes13101789.

Can CSF Biomarkers Decode Contributions of Combined Aβ Plaque, Tau Tangle, and α-Synuclein Pathology?

Knopman DS.

Neurology. 2022 Nov 14;99(20):877-878. doi: 10.1212/WNL.0000000000201287.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias